IMPACT试验:氟康唑围手术期预防真菌感染减少膀胱切除术后并发症的研究方案
本研究为丹麦多中心、双盲、安慰剂对照随机优效性试验,纳入420例拟行膀胱切除加回肠 conduit 的成人患者,1:1随机接受单剂围手术期氟康唑或安慰剂,主要终点为术后90天内Clavien-Dindo III-V级重大并发症,目标将绝对发生率从30%降至18%。
要点
- 膀胱切除加尿流改道术后感染并发症风险高,约50%患者终末回肠样本携带白色念珠菌。
- 当前指南支持围手术期抗生素预防,但尚无抗真菌预防指南。
- 该试验旨在验证围手术期单剂氟康唑能否降低Clavien-Dindo III-V级并发症。
核心结论
- 该试验旨在探索膀胱切除术时预防性抗真菌治疗能否预防术后重大并发症。
研究设计与样本
- 多中心、双盲、安慰剂对照、随机优效性临床试验,纳入丹麦全部五个膀胱切除中心的成人患者。
- 计划纳入420例拟行膀胱切除加回肠 conduit 且无氟康唑禁忌、无活动性真菌感染治疗的成人患者,1:1随机接受单剂围手术期氟康唑或安慰剂。
- 分析采用意向性治疗(ITT)。
主要发现
- 原文未报告试验结果,仅报告研究方案。
关键数值与推荐
- 主要终点为术后90天内Clavien-Dindo III-V级重大并发症。
- 目标将Clavien-Dindo III-V级并发症绝对发生率从30%降至18%。
- 次要终点包括存活且出院天数、胃肠功能、鼻胃管置入、住院时间、再入院、生活质量和微生物学检测结果。
临床怎么用
- 目前指南支持围手术期抗生素预防,但尚无抗真菌预防指南。
- 该试验结果可能为膀胱切除围手术期是否加用抗真菌预防提供证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: Cystectomy with urinary diversion is one of the most complex surgeries in the urological specialty involving surgery on multiple organ systems. The postoperative risk of mortality and complications is considerable, and the first months after surgery are often the most critical. When creating the urinary diversion, the abdominal cavity is exposed to bacteria and fungus from the small intestine, and after the surgery, micro-leakage from the intestinal anastomosis may also contribute to a local infectious response. This contamination is suspected to increase the risk of bowel paralysis that, even with modern ERAS protocols, significantly impacts the postoperative recovery. Emerging data show that approximately 50% of the patients undergoing cystectomy have Candida albicans in samples from the terminal ileum. Current guidelines support the use of perioperative antibiotics, but there are currently no guidelines on antimycotic prophylaxis. We present a randomized clinical trial that tests whether incorporating antimycotics into the perioperative antimicrobial prophylactic regimen can reduce major complications after cystectomy. MATERIALS AND METHODS: This is a multi-center, double-blinded, randomized clinical trial including participants from all five centers in Denmark performing cystectomy. The study includes adult patients planned for cystectomy with an ileal conduit with no contraindications to fluconazole and no active treatment for mycotic infections. The 420 participants are randomized 1:1 to receive a single dose of perioperative fluconazole or placebo. Primary outcome is major postoperative complications, defined as Clavien-Dindo classification III-V, within 90 days following cystectomy. Secondary outcomes are days alive and out of hospital, gastrointestinal function, nasogastric tube placement, length of stay, readmissions, quality of life, and microbiological test results. We aim to reduce the absolute rate of Clavien-Dindo III-V complications from 30 to 18%. The study is a superiority study and analysis will be performed as intention-to-treat. DISCUSSION: Patients undergoing cystectomy face a high risk of surgical complications, many of which can be attributed to infections. There is a growing concern about the consequences of fungal infections after abdominal surgery. This trial aims to explore whether prophylactic antifungal treatment at the time of cystectomy can prevent major postoperative complications. TRIAL REGISTRATION: CTIS EU trial number: 2023-506226-36-00. Registered on February 16, 2024. CLINICALTRIALS: gov: NCT06770530. Registered on March 31, 2024.
引用
- Ynddal MS, Stroomberg HV, Vejlgaard M, et al. IMPACT-Introduction of Mycotic Prophylaxis At Cystectomy Trial: perioperative mycotic prophylaxis with fluconazole to reduce postoperative complications following cystectomy-study protocol for a national multi-center, double-blinded, placebo-controlled, randomized clinical trial. Trials. 2026. PMID: 42380957. doi:10.1186/s13063-026-09862-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。